Chlorcyclizine

Chlorcyclizine Overview

Chlorcyclizine (chemical formula C18H21ClN2) is a first-generation, diphenylpiperazine-derivative H1-antihistamine. Chemically, it belongs to the class of organic compounds known as diphenylmethanes within the benzenoids superclass. Structurally, it features a central 1-(4-chlorobenzhydryl)-4-methylpiperazine skeleton, consisting of a p-chlorodiphenylmethyl (benzhydryl) core attached directly to a methylated piperazine ring.

In clinical immunology, allergy, and vestibular medicine, Chlorcyclizine functions as a systemic H1-receptor antagonist, antiemetic, local anesthetic, and mild anticholinergic agent (ATC code R06AE04). Formulated primarily as Chlorcyclizine hydrochloride in chewable tablets (25 mg), oral liquids, syrups, and combination formulations with decongestants or antitussives (historically marketed under brand names such as Ahist, Bonine for Kids, Di-Paralene, and Mantadil),

What Is Chlorcyclizine and How Does It Work?

Chlorcyclizine acts primarily through competitive antagonism of histamine H1 receptors and vestibular labyrinth central inhibition.

Its primary chemical, physiological, and cellular mechanisms include:

• Competitive Histamine H1 Receptor Blockade: Chlorcyclizine binds competitively and reversibly to histamine H1 receptors on effector cells in vascular smooth muscle, bronchial tissue, gastrointestinal mucosa, and cutaneous nerve endings. By blocking endogenous histamine binding, it inhibits histamine-mediated capillary permeability, microvascular leakage, local edema, and sensory nerve stimulation.
• Allergic Symptom Suppression: In allergic rhinitis and urticaria, H1 receptor blockade suppresses rhinorrhea (runny nose), sneezing, nasal pruritus, lacrimation (watery eyes), and cutaneous wheal-and-flare reactions.
• Secondary Antiserotonergic & Local Anesthetic Properties: Beyond H1 antagonism, Chlorcyclizine exhibits weak 5-HT antiserotonergic activity and sodium channel membrane-stabilizing (local anesthetic) properties.

Is Chlorcyclizine FDA Approved?

Chlorcyclizine hydrochloride is not actively marketed as an FDA-approved prescription brand name today (original prescription approvals such as Di-Paralene were voluntarily discontinued in September 1987). However, it remains legally available in the United States under FDA Over-the-Counter (OTC) Monograph regulations (21 CFR Part 341) as well as select prescription combination products. Under the OTC Monograph system, single-agent formulations (e.g., Ahist) and combination products are permitted for commercial sale for the temporary relief of symptoms associated with allergic rhinitis, upper respiratory allergies, and motion sickness without requiring an individual New Drug Application (NDA) approval.

What Is Chlorcyclizine Used For?

• Symptomatic treatment of seasonal allergic rhinitis (hay fever) and perennial allergic rhinitis.
• Relief of upper respiratory allergy symptoms, including sneezing, rhinorrhea, nasal pruritus, and watery eyes.
• Prevention and symptomatic treatment of motion sickness (nausea, vomiting, and dizziness).
• Symptomatic management of allergic skin conditions, including acute urticaria, angioedema, and allergic pruritus.
• Relief of nasal congestion and rhinorrhea associated with the common cold when combined with sympathomimetic decongestants (e.g., pseudoephedrine or phenylephrine).

Before Taking Chlorcyclizine: Contraindications & Precautions

Evaluate for severe hypersensitivity to Chlorcyclizine, cyclizine, meclizine, hydrohydroxyzine, or other piperazine-derivative antihistamines prior to initiating therapy. Chlorcyclizine is strictly contraindicated in patients taking monoamine oxidase inhibitors (MAOIs) concurrently or within the preceding 14 days, as MAOIs prolong and intensify severe anticholinergic and central nervous system depressant effects. Contraindicated in narrow-angle glaucoma, severe urinary retention, symptomatic prostatic hypertrophy, and acute asthmatic attacks. High-dose animal studies showed piperazine-related teratogenicity (cleft palate); use during pregnancy only if clearly required under medical supervision, and avoid during breastfeeding due to infant sensitivity to anticholinergic effects and respiratory depression.

Who Should Not Take Chlorcyclizine?

• Individuals with a documented severe hypersensitivity to Chlorcyclizine, cyclizine, meclizine, hydroxyzine, or other piperazine-derivative antihistamines.
• Patients taking monoamine oxidase inhibitors (MAOIs) concurrently or within the preceding 14 days, as MAOIs prolong and intensify the anticholinergic and central nervous system depressant effects.
• Patients with narrow-angle glaucoma, severe urinary retention, or symptomatic prostatic hypertrophy, due to anticholinergic exacerbation.
• Patients experiencing acute asthmatic attacks, as anticholinergic drying of bronchial secretions can thicken mucus and worsen airway obstruction.

Chlorcyclizine, Pregnancy & Lactation

Chlorcyclizine crosses the placental barrier. High-dose rodent teratogenicity studies evaluating piperazine derivatives demonstrated congenital cleft palate malformations at massive exposures, though human clinical evidence at therapeutic doses has not established a definitive teratogenic link. Chlorcyclizine should be used during pregnancy only if clearly needed and prescribed by a physician. Chlorcyclizine is excreted in human breast milk; because nursing infants are vulnerable to anticholinergic side effects, irritability, and respiratory depression, use during breastfeeding is generally discouraged.

Tell Your Doctor Before Taking Chlorcyclizine

Inform your physician if you have a history of glaucoma, asthma, chronic obstructive pulmonary disease (COPD), high blood pressure, heart disease, difficulty urinating, enlarged prostate, or liver dysfunction.

Chlorcyclizine Dosage & Administration

Standard adult oral single-agent dosing (25 mg tablets) is 25 mg taken orally every 6 to 8 hours as needed (maximum 75 mg to 100 mg per 24 hours). For motion sickness prevention, administer 25 mg to 50 mg orally 30 to 60 minutes prior to travel. Pediatric oral dosing for children 6 to 12 years is 12.5 mg to 25 mg every 8 to 12 hours as needed (maximum 50 mg per 24 hours); consult a pediatrician for children under 6 years.

Standard Dosing Guidelines

• Adult Oral Dosing (Single-Agent Ahist / 25 mg Tablets): Standard adult dosage is 25 mg taken orally every 6 to 8 hours as needed (maximum 75 mg to 100 mg per 24 hours).
• Adult Motion Sickness Dosing: 25 mg to 50 mg taken orally 30 to 60 minutes prior to travel.
• Pediatric Oral Dosing (Children 6 to 12 Years, e.g., Bonine for Kids): 12.5 mg to 25 mg taken orally every 8 to 12 hours as needed (maximum 50 mg per 24 hours).
• Pediatric Dosing (Children Under 6 Years): Consult a pediatrician for specific weight-based liquid formulations.

How Chlorcyclizine Is Administered

• Administered via the oral route with or without food. Taking doses with food or a glass of milk can reduce mild gastrointestinal upset.
• Chewable tablets should be chewed thoroughly before swallowing.
• Liquid formulations should be measured using a calibrated oral dosing syringe or cup rather than a household spoon.

Chlorcyclizine Clinical Efficacy & Safety Profile

Clinical allergy and travel medicine trials establish that Chlorcyclizine 25 mg provides rapid H1-receptor blockade within 30 to 60 minutes, with a duration of action extending up to 8 to 12 hours due to its piperazine chemical backbone. Comparative clinical studies demonstrate that Chlorcyclizine provides anti-emetic and antipruritic efficacy comparable to meclizine and diphenhydramine. However, like other first-generation antihistamines, its primary clinical limitation is central nervous system drowsiness and anticholinergic dryness compared to non-sedating second-generation H1-antihistamines (such as cetirizine or levocetirizine).

Chlorcyclizine Side Effects & Safety Profile

Chlorcyclizine acts via competitive antagonism of peripheral and central histamine H1 receptors, inhibition of muscarinic cholinergic receptors in the vestibular apparatus and vomiting center, and weak 5-HT antiserotonergic/local anesthetic activity. Common side effects include marked drowsiness, sedation, dizziness, fatigue, dry mouth/throat, and gastrointestinal upset. Serious adverse events include central nervous system depression, paradoxical CNS excitation (restlessness, tremors, seizures, particularly in pediatric/elderly patients), acute urinary retention, closed-angle glaucoma crises, and potential QTc interval prolongation in severe overdose. Original prescription NDA approvals (such as Di-Paralene) were voluntarily discontinued in September 1987, but the agent remains legally marketed in the US under FDA OTC Monograph regulations (21 CFR Part 341).

Common Side Effects

• Central Nervous System: Drowsiness, sedation, dizziness, fatigue, and muscle weakness.
• Anticholinergic Effects: Dry mouth, nose, and throat; thickened bronchial secretions.
• Gastrointestinal: Epigastric distress, nausea, or constipation.

Serious Adverse Events

• Central Nervous System Depression: Severe lethargy, confusion, or marked motor coordination impairment.
• Paradoxical CNS Excitation: Restlessness, irritability, insomnia, tremors, and hyper-reflexia, occurring most frequently in pediatric or elderly patients.
• Anticholinergic Toxicity: Severe urinary retention, acute blurred vision, precipitation of narrow-angle glaucoma, and hyperthermia.
• Cardiac Conduction Effects: Tachycardia, palpitations, and potential QTc interval prolongation in severe overdose or in patients with pre-existing cardiac conduction abnormalities.
• Severe Hypersensitivity: Rare instances of allergic skin rash, angioedema, and anaphylaxis.

Managing Side Effects

If severe drowsiness occurs, avoid operating motor vehicles or machinery. Maintain adequate fluid intake to manage anticholinergic dry mouth.

Chlorcyclizine Drug Interactions & What to Avoid

Co-administration with MAOIs is strictly contraindicated. Combining with alcohol or other central nervous system depressants (opioids, benzodiazepines, barbiturates, sedative-hypnotics) produces synergistic, life-threatening CNS depression and motor impairment. Additive anticholinergic side effects occur when combined with tricyclic antidepressants, atropine, or scopolamine. Avoid alcohol completely during treatment.

Drug-Drug Interactions

• Monoamine Oxidase Inhibitors (MAOIs, e.g., Phenelzine, Selegiline): MAOIs prolong and intensify the anticholinergic and central nervous system depressant effects of first-generation antihistamines. Concurrent use is contraindicated.
• CNS Depressants (e.g., Opioids, Benzodiazepines, Barbiturates, Sedative-Hypnotics): Synergistic additive central nervous system depression, marked sedation, and motor impairment.
• Anticholinergic Medications (e.g., Atropine, Scopolamine, Tricyclic Antidepressants): Additive anticholinergic side effects (urinary retention, severe constipation, confusion).
• QTc-Prolonging Agents: Potential additive effects on cardiac repolarization when co-administered with known QTc-prolonging drugs.

Food & Alcohol

Avoid alcohol consumption during treatment. Alcohol significantly potentiates the central nervous system depressant and sedating effects of Chlorcyclizine, severely impairing alertness and motor coordination.

Chlorcyclizine Overdose, Emergency & Clearance

Chlorcyclizine achieves peak plasma concentrations within 2 to 3 hours following oral administration, undergoes hepatic CYP450 N-demethylation to form its active metabolite norchlorcyclizine, and is excreted renally with an elimination half-life of 10 to 14 hours. Acute overdose causes severe CNS depression or paradoxical excitation (hallucinations, convulsions, respiratory depression), dry flushed skin, hyperthermia, dilated pupils, and cardiac arrhythmias. Management is supportive, including airway protection, IV fluids, and benzodiazepines for seizures. Store tablets and liquids at 20°C to 25°C, protected from moisture and light.

Elimination Kinetics & Overdose

Chlorcyclizine is well absorbed from the gastrointestinal tract, achieving peak plasma concentrations within 2 to 3 hours following oral administration. It is widely distributed into body tissues and crosses the blood-brain barrier. It undergoes hepatic metabolism via Cytochrome P450 pathways (N-demethylation) to form its active metabolite norchlorcyclizine. It is excreted by the kidneys as metabolites and unchanged drug. The elimination half-life is approximately 10 to 14 hours. Acute overdose produces central nervous system depression or severe paradoxical excitation (hallucinations, convulsions, respiratory depression), dry flushed skin, hyperthermia, dilated pupils, and cardiac arrhythmias. Treatment is supportive, including gastric decontamination if recent, airway protection, IV fluids, and benzodiazepines for seizures.

Storage & Handling

Store oral tablets and liquid formulations at controlled room temperature between 20°C and 25°C (68°F to 77°F). Protect from excessive moisture, heat, and direct light. Do not freeze liquid preparations. Keep strictly out of reach of children.

Chlorcyclizine Patient Management & Safety Protocols

Assess the degree of CNS sedation before allowing patients to drive or operate hazardous machinery. Monitor elderly patients closely for anticholinergic complications such as urinary retention, severe constipation, or confusion. Ensure pediatric liquid doses are measured with an accurate oral syringe, and remind patients taking the drug for motion sickness to administer the dose 30 to 60 minutes before departure.

Clinical Monitoring Checklist

• Monitor resolution of allergic rhinitis, motion sickness, or hives.
• Assess degree of central nervous system sedation or drowsiness, especially when initiating therapy.
• Monitor for anticholinergic side effects (urinary retention, dry mouth, blurred vision) in elderly patients.
• Ensure accurate measuring devices are used for pediatric liquid formulations.

Key Do’s and Don’ts

• Do take with food or milk if stomach upset occurs.
• Do take 30 to 60 minutes before travel when using for motion sickness.
• Do use caution when driving or operating machinery due to potential drowsiness.
• Do not consume alcohol while taking Chlorcyclizine.
• Do not take concurrently with MAOI medications or within 14 days of stopping an MAOI.
• Do not give adult-strength formulations to young children without pediatrician guidance.

Frequently Asked Questions

References

• DrugBank Database – Chlorcyclizine Profile (DB08936)
• Classyfire Database – Diphenylmethanes / Piperazine Derivatives Chemical Taxonomy Profile
• Official FDA Over-the-Counter (OTC) Monograph – Cold, Cough, Allergy, and Motion Sickness Drug Products
• Journal of Pharmacology and Experimental Therapeutics – Pharmacokinetics and Dynamics of Piperazine Antihistamines

Legal Disclaimer

The detailed medical and chemical information provided on this specific web page is intended strictly for educational and informational purposes regarding complex pharmacological mechanisms. It absolutely does not constitute professional medical advice, medical diagnosis, or specific treatment recommendations. Always consult a licensed healthcare provider before making any personal decisions regarding complex medical conditions, medication adjustments, or dietary changes.